Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.

Panelists discuss how global LDL thresholds below 55 mg/dL influence care and challenge U.S. practice to evolve. Stay ahead ...

Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...

In an interview with The American Journal of Managed Care® ( AJMC®), Mike Camacho, president of SLTCM, identifies 5 key strategies that ACOs can utilize to improve care and achieve meaningful savings, ...

Treadmill stress echocardiography (TSE) reveals hidden physiologic limitations in patients with asymptomatic hypertrophic cardiomyopathy (HCM), aiding in diagnosis and prognosis. Many patients with ...

Artificial intelligence (AI) is rapidly reshaping the landscape of leukemia diagnosis, offering new possibilities for earlier detection, more precise classification, and improved patient care, ...

Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.

“The monoclonal antibodies rituximab, ocrelizumab, ofatumumab (Kesimpta), and ublituximab (Briumvi) provide outstanding ...

Eleanor Perfetto, PhD, explores how most favored nation policy relates to broader drug pricing and cost-effectiveness debates ...

Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and ...

Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion ...

Hearn Jay Cho, MD, PhD, chief medical officer at the Multiple Myeloma Research Foundation, shared insights on what end points ...